316

4983581

PATENT ABSTRACTS

W O U N D H E A L I N G C O M P O S I T I O N O F I G F - I A N D

T G F - B E T A

Harry N Antoniades, Samuel Lynch assigned to Institute of Molecular Biology lnc; President and Fellows of Harvard Colle

Healing an external wound of a mammal by ad- ministering to the mammal a composition con- taining purified Insulin-like growth factor-I and purified transforming growth factor beta.

4983598

P H A R M A C E U T I C A L C O M P O S I T I O N C O N T A I N I N G

D I L T I A Z E M A N D A N G I O T E N S I N - C O N V E R T I N G E N Z Y M E

I N H I B I T O R

lcilio Cavero, Francois Elkik, Peter Hicks, Jean- Claud Muller, Creteil, France assigned to Syn- thelabo

Compositions of diltiazem and angiotensin- converting enzyme inhibitor useful for the treat- ment of hypertension, cardiac insufficiency and coronary insufficiency.

4983728

N U C L E I C A C I D P R O B E S O F H U M A N P A P I L L O M A V I R U S

Alber Herzog, Alfred Cravador, Sophie Houard, Alex Bollen, Eppegem, Belgium as- signed to Ire-Celltarg S A

The present invention relates to probes of nucleic acids useful for detecting indifferently the various types of human papilloma virus, par- ticularly HPVla, HPV5, HPV6b, HPVS, HPVI 1, HPVI6, HPVI8 and HPV33, especially a probe comprising a labelled sequence of nucleic acids, characterized in that it comprises the oligomer of twelve nucleotides X-A-A-A-A-C- G-A-A-A-G-X, with X = T or U, or its comple- ment by interchanging A and X on the one hand, C and G on the other hand. The present inven- tion also relates to specific probes of nucleic ac- ids for the detection of human papilloma for each of the types HPVla, HPV5, HPV8, HPVI 1, HPV16, HPV18 and HPV33, as well as specific

probes of sub-groups of the virus HPVI6, HPVI8, HPV33 or HPV16 and HPV18 only or again HPV5 and HPV8 only.

4985243

C O M P O S I T I O N A N D M E T H O D F O R P R O T E C T I N G A G A I N S T

D I S E A S E S C A U S E D BY M I C R O O R G A N I S M S

Daryl H Faulds, Mimi Vishoot assigned to ML Technology Ventures L P

A vaccine for protecting against a disease caused by a microorganism which does not synthesize nucleic acid precursors such as a Micoplasma or- ganism, which contains nuclease and/or a nuclease fragment or derivative which produces antibodies which recognize nuclease secreted or available on the surface of the microorganism against which protection is to be afforded. A vac- cine may also be prepared from an antibody or fragment or derivative thereof which recognizes such nuclease of such microorganism.

4985244

S T A B I L I Z E D L I V E A T T E N U A T E D V A C C I N E A N D I T S P R O D U C T I O N

Satoshi Makino, Keiko Sasaki, Masaharu Nakagawa, Kanagawa, Japan assigned to The Kitasato Institute

A stabilized live attenuated vaccine with im- proved thermal stability, which comprises a live attenuated plain vaccine consisting of measles, mumps or rubella virus grown in a medium-199 for cell culture, or a combined live attenuated vaccine thereof, containing a stabilizing agent at a final concentration of lactose 2.5-5 W/V o/, saccharose 2.5-5 W/V %, D-sorbitol 1.8-2 W/V %, sodium glutamate about 0.1 W/V % and gelatin hydrolyzate, M.W. approx. 35,000, 2-3 w / v %.

~ 8 5 ~ 6

C O M P O S I T I O N O F M A T T E R F O R I N H I B I T I N G L E U K E M I A S A N D

S A R C O M A S

George Pettit assigned to Arizona Board of Re- gents